Trial Profile
A 5-month, prospective, open-label, nonrandomized single-center study to evaluate the effects of addition of Ivabradine to β-Blocker improves exercise capacity in systolic heart failure patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary) ; Carvedilol
- Indications Heart failure
- Focus Therapeutic Use
- 08 Dec 2015 New trial record